FDA Approves Jemperli as Frontline Treatment for Advanced Endometrial Cancer.

The article focuses on the Food and Drug Administration approval of Jemperli as a frontline treatment for patients with advanced or recurrent endometrial cancer. The topics include the significance of Jemperli as the first immuno-oncology treatment for this patient population, its indication for patients with mismatch repair deficient microsatellite instability-high in combination with carboplatin and paclitaxel, and the reduction in disease progression or death risk.